Omeros (OMER) Cash from Investing Activities (2010 - 2026)
Omeros (OMER) reported Cash from Investing Activities of $28.7 million for Q1 2026, down 25.45% on a YoY basis from $38.5 million in Q1 2025, and down 74.24% sequentially from $111.5 million in Q4 2025.
Omeros (OMER) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Omeros (OMER) has 17 years of Cash from Investing Activities data on file, last reported at $28.7 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 25.45% year-over-year to $28.7 million; the trailing twelve-month figure through Mar 2026 stood at $154.7 million (down 15.31% YoY), and the FY2025 full-year result was $164.5 million, up 100.11% from the prior year.
- Cash from Investing Activities slipped to $28.7 million in Q1 2026, from $111.5 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $116.2 million in Q4 2023 to a low of -$181.3 million in Q1 2023.
- A 5-year average of $10.3 million and a median of $33.0 million in 2022 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities tumbled 332.87% in 2022 and surged 219.12% in 2025, its largest moves.
- Tracing OMER's Cash from Investing Activities over 5 years: stood at -$108.5 million in 2022, then surged by 207.15% to $116.2 million in 2023, then sank by 69.93% to $35.0 million in 2024, then surged by 219.12% to $111.5 million in 2025, then slumped by 74.24% to $28.7 million in 2026.
- Business Quant data shows OMER's Cash from Investing Activities at $28.7 million in Q1 2026, $111.5 million in Q4 2025, and -$6.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - | 172.62 Mn |
| 10 | Omeros | 805.83 Mn | 805.83 Mn | 9.31 Mn | 28.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.73 Mn |
| Mar 31, 2026 | 28.73 Mn |
| Dec 31, 2025 | 111.55 Mn |
| Dec 31, 2025 | 111.55 Mn |
| Sep 30, 2025 | -6.86 Mn |
| Sep 30, 2025 | -6.86 Mn |
| Jun 30, 2025 | 21.30 Mn |
| Jun 30, 2025 | 21.30 Mn |
| Mar 31, 2025 | 38.54 Mn |
| Mar 31, 2025 | 38.54 Mn |
| Dec 31, 2024 | 34.95 Mn |
| Dec 31, 2024 | 34.95 Mn |
| Sep 30, 2024 | 36.04 Mn |
| Sep 30, 2024 | 36.04 Mn |
| Jun 30, 2024 | 73.15 Mn |
| Jun 30, 2024 | 73.15 Mn |
| Mar 31, 2024 | -61.93 Mn |
| Mar 31, 2024 | -61.93 Mn |
| Dec 31, 2023 | 116.24 Mn |
| Dec 31, 2023 | 116.24 Mn |